Dott. Guido Palamara
Dermatologo Roma
Dott. Guido Palamara, Dermatologo a Roma
Dott. Guido Palamara
Dermatologia e Venereologia
Visita Specialistica Dermatologica e Dermatovenereologica
Visita Specialistica Malattie Sessualmente Trasmesse
Epiluminescenza con VideoMicroscopia e Mappa Nevica
Crioterapia, Diatermocoagulazione
Piccola Chirurgia Cutanea, Asportazione Nevi
Telefono Dermatologo Roma, Appia

Dott. Guido Palamara

Responsabile: Dermatologia Infettiva
Istituto Dermatologico San Gallicano IRCSS - Roma

Nato a Roma il 26.01.1948 , dopo aver conseguito la Licenza Liceale Scientifica si laurea presso l’Università “La Sapienza” di Roma in Scienze Biologiche nel 1971.

Nel 1976 consegue la Specializzazione in Analisi Chimico-cliniche e microbiologiche.

Dal 1972 al 1980 dirige il Reparto di Farmaco-tossicologia della Polifarma di Roma.

Dal 1980 ricopre il ruolo di Assistente del Reparto di Microbiologia e Micologia Sperimentale dell’Istituto S. Gallicano di Roma.

Nel 1984 consegue la laurea in Medicina e Chirurgia presso l’Università “La Sapienza” di Roma dove nel 1987 si specializza in Dermatologia e Venereologia.

Nel 1990 viene nominato Aiuto Medico nel Reparto di Microbiologia e micologia Sperimentale e nominato responsabile della Sezione di Batteriologia e Microbiologia.

Dott. Guido Palamara

Nel 1998 viene nominato Dirigente Medico di I Livello presso la U.O.C. di Dermatologia Infettiva e nominato Responsabile della U.O. HIV/AIDS di III Livello.

Dal 2006 ricopre il ruolo di Direttore della U.O.C. di Dermatologia Infettiva dell’ISG.

Membro della SIDEMAST e della SIMIT. Membro del CIO (Comitato Infezioni Ospedaliere) dell’ISG.

In questi anni è stato relatore in numerosi Congressi Nazionali e Internazionali e ha pubblicato più di 100 lavori , 25 dei quali indicizzati.

Numerose le sperimentazioni cliniche sia in campo dermatologico che infettivologico con particolare riguardo alle infezioni da HIV, HPV e HSV.

Ha partecipato alla sperimentazione di fase I del vaccino anti-TAT dell’Istituto Superiore di Sanità (Barbara Ensoli) ed è Investigatore Principale (PI) della fase II dello stesso vaccino.

Ha partecipato alla sperimentazione expanded access di alcuni farmaci antiretrovirali come il Raltegravir e l’Etravirina nonché responsabile per il S. Gallicano del progetto GNOMO sullo studio del Tenofovir.

Dal 2004 in collaborazione con il Laboratorio di Virologia dell’Università “Tor Vergata” di Roma (prof. Carlo Federico Perno) svolge una ricerca sulla genotipizzazione del virus HIV in soggetti naive e in fallimento viro-immunologico.

Responsabile della Linea I della Ricerca Corrente dell’ISG.

La U.O.C. di Dermatologia e Venereologia è il Centro di riferimento per tutte le Cliniche infettivologiche del Lazio per la diagnosi e cura delle Malattie Sessualmente Trasmesse (Sifilide, gonorrea, clamidia, micoplasmi, HPV, herpes etc.) e uno dei più importanti Centri per la diagnosi e terapia della infezione da HIV avendo circa 450 pazienti in follow-up e 200 in terapia antiretrovirale.



Radiation recall dermatitis in course of epidemic Kaposi's sarcoma.

Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.

Impact of pre-therapy viral load on virological response to modern first-line HAART.

The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing.

Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.

Anal cytological abnormalities and epidemiological correlates among men who have sex with men at risk for HIV-1 infection.

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.

Effective treatment of Kaposi's sarcoma by electrochemotherapy and intravenous bleomycin administration.

The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients.

Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010.

Prevalence, genotype diversity and determinants of anal HPV infection in HIV-uninfected men having sex with men.

Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.

Hepatitis C Virus Infection Among non-IDU HIV-Infected and Uninfected Men who Have Sex with Men.

'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing.

A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen.

Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study.

A novel methodology for large-scale phylogeny partition.

No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy.

Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.

Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.

Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy.

Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.

No evidence of colonization with community-acquired methicillin-resistant Staphylococcus aureus in HIV-1-infected men who have sex with men.

Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test.

Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate.

The preventive phase I trial with the HIV-1 Tat-based vaccine.

CD81 expression on CD19+ peripheral blood lymphocytes is associated with chronic HCV disease and increased risk for HCV infection: a putative role for inflammatory cytokines.

Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.

Azithromycin-resistant Neisseria gonorrhoeae strains recently isolated in Italy.

Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.

Non-B HIV type 1 subtypes among men who have sex with men in Rome, Italy.

Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.

Molecular analysis of tetracycline-resistant gonococci: rapid detection of resistant genotypes using a real-time PCR assay.

Incidence of human herpesvirus 8 (HHV-8) infection among HIV-uninfected individuals at high risk for sexually transmitted infections.

Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.

Increased HIV incidence among men who have sex with men in Rome.

The clinical appearance of pinta mimics secondary syphilis: another trap of treponematosis?

Evidence of an outbreak of syphilis among men who have sex with men in Rome.

[Screening for HIV-1 infection targeted to women at a center for sexually transmitted diseases (STD). Comparison between 2 periods of 5 years of work].

Risk factors for HTLV-I and II in individuals attending a clinic for sexually transmitted diseases.

Incidence and determinants of hepatitis C virus infection among individuals at risk of sexually transmitted diseases attending a human immunodeficiency virus type 1 testing program.

Epidemiology of dermatophytoses observed in Rome, Italy, between 1985 and 1993.

In vitro adherence of Neisseria gonorrhoeae to human epithelial cells.

Prevalence of antibodies to human immunodeficiency virus type 1 and condom use among outpatients at a sexually transmitted disease clinic in Rome.

Behaviour of several 'progression markers' during the HIV-Ab seroconversion period. Comparison with later stages.

Seroprevalence of anti-Chlamydia trachomatis IgG in outpatients attending a sexually transmitted disease clinic in Italy.

Prevalence of Chlamydia trachomatis in cases of genital non-gonococcal infection according to microbiological and serological investigations.

Distribution and frequency of dermatophytes in the city of Rome between 1978 and 1983.

An experimental model for transepidermal elimination of a dermatophytic granuloma.

[Isolation of Neisseria meningitidis from homosexual men].

On a case of suberythrodermic chronic tinea by Trichophyton violaceum.

[Pharmacologic activity of dihydroergotoxine methanesulfonate and its constituents].

[Preliminary study of the effects of nicotinic-N-oxide acid causing hypolipidemia administered alone or in combination with clofibrate].

[Further studies of the action of an anti-inflammatory agent recently used in therapy].

Torna SU